Floatz logo

Busulphan

Core Binding Factor Alpha Subunits

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Core Binding Factor Alpha Subunits cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2CCC
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2CCC
TACROLIMUS
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Romidepsin
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →